Maximizing the success of HIV+ to HIV+ kidney transplantation in South Africa
Project Number5U01AI152153-05
Contact PI/Project LeaderMULLER, ELMI
Awardee OrganizationUNIVERSITY OF CAPE TOWN
Description
Abstract Text
Project Summary:
We previously demonstrated that the patient and graft survival rates for HIV+ to HIV+ kidney transplants are
comparable to rates seen in other HIV+ transplant recipients. We also showed that these transplants do not
result in sustained HIV superinfection despite presence of a detectable donor viral inoculum in these recipients,
alleviating one of the major concerns with these surgeries.
This proposal aims to expand on these novel findings by initially exploring how the immune modulators these
patients receive may affect the HIV latent viral reservoir, which is the primary hurdle in the search for an HIV
cure. In addition, we and others have observed a possible increased risk of rejection in HIV+ kidney transplant
recipients in general. Therefore, we have partnered with the HIV transplant and pathology groups at UCSF, as
well as a team of other collaborators from the US, Spain, and South Africa, to examine the role of several
components of the immune response associated with organ rejection. We will also utilize this diverse team of
experts in HIV infectious disease, pathology, and transplantation to increase clinical and laboratory support for
transplantation services in underserved areas in South Africa, thereby increasing availability of these life-
saving transplants.
The results of this study will have a direct and immediate influence on transplant clinical practice in South
Africa and the US. Additionally, our study provides an opportunity to answer multiple fundamental biological
questions surrounding HIV cure research and HIV related organ rejection.
Public Health Relevance Statement
Project Narrative:
Our team in South Africa has successfully performed 51 HIV+ to HIV+ kidney transplants. This proposal will
build on these positive findings, and utilize this unique population to explore HIV latency, examine causes of
organ rejection, and expand access to these life-saving transplants by implementing novel eMedicine
programs to strengthen clinical management and support in underserved areas of South Africa.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
568227214
UEI
NN5NML6VUCF9
Project Start Date
06-April-2020
Project End Date
31-March-2026
Budget Start Date
01-April-2024
Budget End Date
31-March-2026
Project Funding Information for 2024
Total Funding
$159,840
Direct Costs
$148,000
Indirect Costs
$11,840
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$159,840
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U01AI152153-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01AI152153-05
Patents
No Patents information available for 5U01AI152153-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01AI152153-05
Clinical Studies
No Clinical Studies information available for 5U01AI152153-05
News and More
Related News Releases
No news release information available for 5U01AI152153-05
History
No Historical information available for 5U01AI152153-05
Similar Projects
No Similar Projects information available for 5U01AI152153-05